Assessment of cognitive impairment using FP-CIT SPECT
Objective: We aimed to assess the cognitive impairment using FP-CIT SPECT in mild cognitive impairment or dementia patients. Background: In general, FP-CIT SPECT reflect pre-synaptic dopamine…Orthostatic myoclonus after brain tumor surgery and radiation
Objective: To review the clinical and electrophysiological characteristics of orthostatic myoclonus (OM) in the setting of brain tumor treatment, a novel association. Background: OM is…Putaminal Diffusion Imaging for the Differential Diagnosis of the Parkinsonian Variant of Multiple System Atrophy from Parkinson’s Disease: Impact of Segmentation Accuracy
Objective: To evaluate different approaches of segmentation of the putamen in order to discriminate PD from MSA-P based on putaminal diffusion imaging. Background: Differences in prognosis…The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments
Objective: To review the outcome of continuous apomorphine infusion (CAI) in advanced Parkinson’s disease (PD) patients at the rehabilitation unit of the Parkinson Expertise Center…Dextrometorphan/quinidine in Atypical Parkinsonisms and Huntington Disease
Objective: to determine whether Dextrometorphan/quinidine (DMQ) is effective in the treatment of PBA, AG or bulbar symptoms in corticobasal syndrome (CBS), multiple system atrophy (MSA),…Validation of a performance-based assessment of functional ability related to cognition in Parkinson’s disease
Objective: Validate the University of California San Diego Performance-Based Skills Assessment (UPSA) in Parkinson's disease (PD) Background: Diagnostic criteria for PD dementia (PDD) require significant…Cognitive strategy use during daily activities in people with Parkinson’s Disease
Objective: To identify difficulties in cognitive strategy use observed in people with Parkinsons’s disease (PD) during performance of everyday activities. Background: People use cognitive strategies…The clinical profile associated to Amyloid-beta 42 and Tau cerebrospinal fluid levels in non-demented PD patients
Objective: To define cerebrospinal fluid (CSF) levels of Amyloid-beta 1-42 (Aß1-42-), total (h-) and phosphorylated (p-)Tau in a large cohort of non-demented Parkinson’s disease (PD)…Pro-saccades predict decline in attention over 18months in newly diagnosed Parkinson’s disease
Objective: This study investigated 1) pro-saccades in a newly diagnosed cohort of Parkinson’s disease (PD) compared to healthy older adult controls at baseline, and 2)…Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease
Objective: We investigated which clinical-ready and cost-effective markers are predictive of cognitive impairment (CI) in Parkinson’s disease (PD) in a cohort of 294 patients with…
- « Previous Page
- 1
- …
- 137
- 138
- 139
- 140
- 141
- …
- 155
- Next Page »